The Trump administration’s recent release of a series of drug pricing executive orders is leading to more questions than answers. While all four lack clear and sustainable pathways to reducing drug costs for all, the order to revive and finalize the so-called rebate rule – which the Administration proposed and then withdrew last year – is especially strange in its logic.
Pharmaceutical Care
Management Association
505 9th Street NW, 10th Floor, Washington, DC 20004
© 2026 PCMA. All Rights Reserved.